The Myoclonic Seizure drugs in development market research report provides comprehensive information on the therapeutics under development for Myoclonic Seizure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Myoclonic Seizure. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Myoclonic Seizure and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Myoclonic Seizure by eight companies/universities/institutes. The top development phase for Myoclonic Seizure is preclinical with six drugs in that stage. The Myoclonic Seizure pipeline has nine drugs in development by companies and one by universities/ institutes. Some of the companies in the Myoclonic Seizure pipeline products market are: Taysha Gene Therapies, Ionis Pharmaceuticals and Jazz Pharmaceuticals.
The key targets in the Myoclonic Seizure pipeline products market include Adenosine Monophosphate Activated Protein Kinase, Lysosomal Alpha Glucosidase, and Glycogen Starch Synthase.
The key mechanisms of action in the Myoclonic Seizure pipeline product include Adenosine Monophosphate Activated Protein Kinase Activator with one drug in Preclinical. The Myoclonic Seizure pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Myoclonic Seizure pipeline products market including Small Molecule, and Gene Therapy.
Myoclonic Seizure overview
Myoclonic seizures cause a quick, uncontrollable muscle movement with no change in level of awareness or consciousness. They are characterized by brief, jerking spasms of a muscle or a group of related muscles, but can sometimes affect wider areas of body.
For a complete picture of Myoclonic Seizure’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
